Jonathan P.  Foster net worth and biography

Jonathan Foster Biography and Net Worth

Executive VP & Chief Financial Officer of Moleculin Biotech

Mr. Foster has served as our Chief Financial Officer and Executive Vice President since August 2016. Mr. Foster brings more than 40 years in financial experience holding a variety of executive and senior financial positions with public, private, start-up to large corporate and international companies. This includes over 20 years as Chief Financial Officer of public companies. And over 7 years as a board member of public companies.

From February 2012 to August 2016, Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG. In the 1990’s he served as Executive Vice President and Chief Financial Officer of Drypers Corporation, a Nasdaq listed consumer products company. Prior to that Mr. Foster served in various C-suite capacities with public and private companies with his start beginning as Manager at Deloitte & Touche, LLP. Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012. He served on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, from June 2018 until December 2021. At Soliton he was the chair of the Audit and Compensation Committees and the past chair of the Nominating & Governance Committee. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. Since June 2021, Mr. Foster has served on the Board of Directors of Volcon, Inc., now Empery Digital, Inc. (EMPD), a company listed on Nasdaq, where he is the past chair and current member of the Audit Committee, a member of the Nominating & Governance Committee and is the Chair of the Compensation Committee. Mr. Foster has also served on the Board of Directors of Autonomix Medical, Inc. (AMIX), a medical device company listed on Nasdaq, since January 2022. There he serves as the chair of the Audit and Compensation committees. Mr. Foster is a Certified Public Accountant (South Carolina) and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985.

What is Jonathan P. Foster's net worth?

The estimated net worth of Jonathan P. Foster is at least $5.12 thousand as of June 23rd, 2025. Mr. Foster owns 11,503 shares of Moleculin Biotech stock worth more than $5,125 as of October 7th. This net worth approximation does not reflect any other assets that Mr. Foster may own. Learn More about Jonathan P. Foster's net worth.

How do I contact Jonathan P. Foster?

The corporate mailing address for Mr. Foster and other Moleculin Biotech executives is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. Moleculin Biotech can also be reached via phone at (713) 300-5160 and via email at [email protected]. Learn More on Jonathan P. Foster's contact information.

Has Jonathan P. Foster been buying or selling shares of Moleculin Biotech?

Jonathan P. Foster has not been actively trading shares of Moleculin Biotech during the past quarter. Most recently, on Monday, June 23rd, Jonathan P. Foster bought 10,810 shares of Moleculin Biotech stock. The stock was acquired at an average cost of $9.25 per share, with a total value of $99,992.50. Following the completion of the transaction, the chief financial officer now directly owns 11,503 shares of the company's stock, valued at $106,402.75. Learn More on Jonathan P. Foster's trading history.

Jonathan P. Foster Insider Trading History at Moleculin Biotech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/23/2025Buy10,810$9.25$99,992.5011,503View SEC Filing Icon  
12/26/2023Buy77$258.75$19,923.75214View SEC Filing Icon  
4/25/2017Buy26$322.50$8,385.0026View SEC Filing Icon  
See Full Table

Jonathan P. Foster Buying and Selling Activity at Moleculin Biotech

This chart shows Jonathan P. Foster's buying and selling at Moleculin Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moleculin Biotech Company Overview

Moleculin Biotech logo
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $0.45
Low: $0.44
High: $0.46

50 Day Range

MA: $0.62
Low: $0.39
High: $1.36

2 Week Range

Now: $0.45
Low: $0.16
High: $15.75

Volume

42,957 shs

Average Volume

647,549 shs

Market Capitalization

$8.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2